



Global survey of genetic testing methods for familial hypercholesterolaemia: a study and recommendations from the European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration registry

Joana Rita Chora ^{1,2,3†}, Irene Karungi^{4†}, Amany Elshorbagy ^{4,5}, Christophe A.T. Stevens⁴, Antonio J. Vallejo-Vaz^{4,6,7,8}, Kanika I. Dharmayat⁴, Marianne Abifadel⁹, Carlos A. Aguilar-Salinas ^{10,11}, Khalid F. Alhabib¹², Wael Almahmeed¹³, Fahad Alnouri¹⁴, Rodrigo Alonso ¹⁵, Khalid Al-Rasadi¹⁶, Ahmad Al-Sarraf¹⁷, Marcello Arca^{18,19}, Engy A. Ashaat²⁰, Tester F. Ashavaid²¹, Maurizio Averna^{22,23}, Maciej Banach^{24,25,26}, Marianne Becker²⁷, Christoph J. Binder²⁸, Liam R. Brunham ²⁹, Alberico L. Catapano^{30,31}, Pablo Corral ³², Olivier S. Descamps³³, Euridiki Drogari³⁴, Ronen Durst ³⁵, Marat Ezhov³⁶, Urh Groselj ^{37,38}, Mariko Harada-Shiba³⁹, Kirsten B. Holven^{40,41}, G. Kees Hovingh^{42,43}, Weerapan Khovidhunkit⁴⁴, Katarina Lalic⁴⁵, Gustavs Latkovskis⁴⁶, Ulrich Laufs ⁴⁷, Evangelos Liberopoulos ⁴⁸, Jie Lin⁴⁹, Winfried März ^{50,51,52,53}, Pedro Mata⁵⁴, Anne Thushara Matthias⁵⁵, André R. Miserez^{56,57,58}, Olena Mitchenko⁵⁹, Hapizah Mohd Nawawi⁶⁰, Børge G. Nordestgaard ⁶¹, Andrie G. Panayiotou⁶², György Paragh⁶³, Zaneta Petrulioniene⁶⁴, Arman Postadzhiyan⁶⁵, Ximena Reyes⁶⁶, Fouzia Sadiq⁶⁷, Amirhossein Sahebkar ^{68,69}, Raul D. Santos ⁷⁰, J.P.S. Sawhney⁷¹, Heribert Schunkert^{72,73}, Swarup A.V. Shah⁷⁴, Aleksandr B. Shek⁷⁵, Handrean Soran ⁷⁶, Ta-Chen Su⁷⁷, Tavintharan Subramaniam⁷⁸, Myra Tilney⁷⁹, Brian Tomlinson⁸⁰, Thanh Huong Truong⁸¹, Anne Tybjærg-Hansen ^{82,83}, Margus Viigimaa ⁸⁴, Branislav Vohnout⁸⁵, Gerald F. Watts^{86,87}, Shizuya Yamashita⁸⁸, Kausik K. Ray ⁴, Frederick J. Raal⁸⁹, Steve E. Humphries⁹⁰, Tomas Freiburger ^{91,92}, and Mafalda Bourbon ^{1,2,3*} on behalf of the EAS FHSC

¹Unidade de Investigação e Desenvolvimento, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Av. Padre Cruz, 1649-016 Lisbon, Portugal; ²Biosystems & Integrative Sciences Institute (BioISI), Faculty of Sciences, University of Lisbon, Campo Grande, 1749-016 Lisbon, Portugal; ³Cardiovascular Centre of the University of Lisbon (CCUL@RISE, CAML), Faculty of Medicine, University of Lisbon, Avenida Professor Egas Moniz, 1649-028 Lisbon, Portugal; ⁴Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care

* Corresponding author. Tel: +351 217 508 126, Email: mafalda.bourbon@insa.min-saude.pt

† The first two authors are co-first authors.

© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

and Public Health, School of Public Health, Imperial College London, London, UK; ⁵Department of Physiology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt; ⁶Department of Medicine, Faculty of Medicine, University of Seville, Seville, Spain; ⁷Clinical Epidemiology and Vascular Risk, Instituto de Biomedicina de Sevilla, IBIH/Hospital Universitario Virgen del Rocío/Universidad de Sevilla/CSIC, Seville, Spain; ⁸Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain; ⁹Laboratory of Biochemistry and Molecular Therapeutics, Faculty of Pharmacy, Saint Joseph University, Beirut, Lebanon; ¹⁰Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México; ¹¹Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico; ¹²Department of Cardiac Sciences, King Fahad Cardiac Centre, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia; ¹³Cleveland Clinic Abu Dhabi, Heart and Vascular Institute, Abu Dhabi, United Arab Emirates; ¹⁴Cardiovascular Prevention Unit, Adult Cardiology Department, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia; ¹⁵Centre for Advanced Metabolic Medicine and Nutrition, Santiago, Chile; ¹⁶Department of Biochemistry, College of Medicine and Health Science and Medical Research Centre, Sultan Qaboos University, Muscat, Oman; ¹⁷Sabah Al Ahmad Cardiac Centre, Kuwait City, Kuwait; ¹⁸Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; ¹⁹Department of Medicina Interna e Specialità Mediche, AO Policlinico Umberto I, Rome, Italy; ²⁰Clinical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt; ²¹Department of Laboratory Medicine, P.D. Hinduja Hospital and Medical Research Centre Mahim, Mumbai, India; ²²Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Università degli Studi di Palermo, Palermo, Italy; ²³Institute of Biophysics (IBF), National Research Council (CNR), Palermo, Italy; ²⁴Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; ²⁵Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland; ²⁶Collegium Medicum, John Paul II Catholic University of Lublin, Lublin, Poland; ²⁷Department of Pediatric Endocrinology and Diabetology, Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg; ²⁸Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; ²⁹Departments of Medicine and Medical Genetics, Centre for Heart Lung Innovation, The University of British Columbia, Vancouver, Canada; ³⁰Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; ³¹Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Sesto San Giovanni, Milan, Italy; ³²Pharmacology Department, FASTA University, School of Medicine, Mar del Plata, Argentina; ³³Department of Internal Medicine, Centres Hospitaliers Universitaires HELORE at La Louvière and University of Mons, Mons, Belgium; ³⁴First Department of Pediatrics, Unit of Inherited Metabolic Disorders and Inherited Dyslipidaemias, Choremio Research Institute, National and Kapodistrian University of Athens, Athens, Greece; ³⁵Cardiology Department and Centre for Treatment and Prevention of Atherosclerosis, Hadassah Hebrew University Medical Centre, Jerusalem, Israel; ³⁶National Medical Research Centre of Cardiology n.a. Acad. E.I. Chazov, Ministry of Health of the Russian Federation, Moscow, Russia; ³⁷Department of Endocrinology, Diabetes and Metabolism, University Medical Centre, University Children's Hospital Ljubljana, Ljubljana, Slovenia; ³⁸Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; ³⁹Osaka Medical and Pharmaceutical University, Takatsuki, Japan; ⁴⁰Department of Nutrition, Medical Faculty, University of Oslo, Oslo, Norway; ⁴¹Norwegian National Network on Familial Hypercholesterolemia, Oslo University Hospital, Oslo, Norway; ⁴²Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; ⁴³Novo Nordisk, Soborg, Denmark; ⁴⁴Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand; ⁴⁵Faculty of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University of Belgrade, Belgrade, Serbia; ⁴⁶Faculty of Medicine and Life Sciences, Research Institute of Cardiology and Regenerative Medicine, University of Latvia, Pauls Stradins Clinical University Hospital, Riga, Latvia; ⁴⁷Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany; ⁴⁸First Department of Propaedeutic and Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; ⁴⁹Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; ⁵⁰DACH Society for the Prevention of Heart and Circulatory Diseases, Hamburg, Germany; ⁵¹Medical Clinic III (Cardiology, Pneumology, Angiology), University of Heidelberg, Heidelberg, Germany; ⁵²Clinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; ⁵³Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim and Augsburg, Germany; ⁵⁴Fundación Hipercolesterolemia Familiar, Madrid, Spain; ⁵⁵Department of Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka; ⁵⁶Diagene Research Institute, Breitenbach, Reinach, Switzerland; ⁵⁷Swiss Society for Familial Forms of Hypercholesterolemia (SSFH), Breitenbach, Switzerland; ⁵⁸Faculty of Medicine, University of Basel, Basel, Switzerland; ⁵⁹Department of Dyslipidaemia, Institute of Cardiology, National Academy of Medical Sciences, Kiev, Ukraine; ⁶⁰Specialist Lipid Clinics, Hospital Al-Sultan Abdullah (HASA), Universiti Teknologi MARA (UiTM) Teaching Hospital, Puncak Alam, and Management & Science University (MSU), Shah Alam, Selangor, Malaysia; ⁶¹Copenhagen University Hospital—Herlev and Gentofte, University of Copenhagen, Copenhagen, Denmark; ⁶²Department of Rehabilitation Sciences, School of Health Sciences, Cyprus University of Technology, Limassol, Cyprus; ⁶³Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; ⁶⁴Vilnius University Faculty of Medicine and Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; ⁶⁵Medical University of Sofia, Sofia, Bulgaria; ⁶⁶GENYCO Program, Comisión Honoraria Para la Salud Cardiovascular, Montevideo, Uruguay; ⁶⁷Directorate of Research, Shifa Tameer-e-Millat University, Islamabad, Pakistan; ⁶⁸Center for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College and Hospitals, Saveetha University, Chennai, India; ⁶⁹Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; ⁷⁰Heart Institute (InCor), University of São Paulo and Hospital Israelita Albert Einstein, São Paulo, Brazil; ⁷¹Department of Cardiology, Sir Ganga Ram Hospital, New Delhi, India; ⁷²Clinic for Heart and Circulatory Diseases, German Heart Centre Munich, Technical University Munich, Munich, Germany; ⁷³German Centre for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany; ⁷⁴Department of Laboratory Medicine, PD Hinduja Hospital and Medical Research Centre Mahim, Mumbai, India; ⁷⁵Department of Coronary Heart Disease and Atherosclerosis, Republican Specialized Centre of Cardiology, Ministry of Health of Republic Uzbekistan, Tashkent, Uzbekistan; ⁷⁶NIHR/Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK; ⁷⁷Division of Cardiology, Department of Internal Medicine, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan; ⁷⁸Admiralty Medical Centre and Khoo Teck Puat Hospital, Yishun Health, Yishun Central, Singapore; ⁷⁹Lipid Clinic, Department of Medicine, Mater Dei Hospital, University of Malta, Msida, Malta; ⁸⁰Faculty of Medicine, Macau University of Science and Technology, Macau, China; ⁸¹Faculty of Medicine, Phenikaa University, and Cardiovascular Center, Phenikaa University Hospital, Hanoi, Vietnam; ⁸²Department of Clinical Biochemistry, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark; ⁸³Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ⁸⁴North Estonia Medical Centre, Tallinn University of Technology, Tallinn, Estonia; ⁸⁵Department of Diabetology, LF SZU, Institute of Nutrition, FOaZOS, Coordination Centre for Familial Hyperlipidemias, Slovak Medical University in Bratislava, Bratislava, Slovakia; ⁸⁶School of Medicine, University of Western Australia, Perth, WA, Australia; ⁸⁷Lipid Disorders Clinic, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital, Perth, WA, Australia; ⁸⁸Rinku General Medical Centre, Osaka, Japan; ⁸⁹Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ⁹⁰Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, UK; ⁹¹Centre for Cardiovascular Surgery and Transplantation, and Medical Faculty, Masaryk University, Brno, Czechia; and ⁹²CarDia—National Institute for Metabolic and Cardiovascular Disease Research, Czechia

Received 30 October 2025; revised 10 December 2025; accepted 31 March 2026; online publish-ahead-of-print 14 May 2026

Aims

Familial hypercholesterolaemia (FH), primarily caused by pathogenic *LDLR*, *APOB*, or *PCSK9* variants, results in elevated LDL cholesterol and increased cardiovascular risk. Genetic testing offers the definitive diagnosis, yet global approaches to FH genetic testing remain unstandardized. We investigate current testing practices worldwide and provide relevant recommendations.

Methods and results

A survey was distributed to national lead investigators of 68 countries in the Familial Hypercholesterolaemia Studies Collaboration, assessing referral criteria, assay methodologies, target genes, and pathogenicity interpretation methods. National lead investigators from centres in 55/68 countries (81%) responded, spanning Africa ($n = 2$), Americas

(*n* = 6), Asia (*n* = 20), Europe (*n* = 26), and Oceania (*n* = 1). Dutch Lipid Clinic Network (DLCN) scores were the most common reason for referral to genetic testing (adults, 72%; children, 57%). Simon–Broome and Make Early Diagnosis to Prevent Early Death (MEDPED) criteria were reported only by centres from high-income countries (adults, 7% and 2%; children, 12% and 2%). Methods for testing in index vs. non-index cases were significantly different (*P* < 0.001). Next-generation sequencing (NGS) was the predominant assay method for index cases (62%), while Sanger sequencing was favoured for non-index (71%). However, these testing techniques did not differ between centres from high- and non-high-income countries for index cases (*P* = 0.74) and non-index cases (*P* = 0.49). Copy-number variants (CNVs) were assessed by 65% of centres, with most integrating CNV analysis into NGS platforms (86%) and others (14%) using multiplex ligation-dependent probe amplification (MLPA) or microarrays. Screening encompassed *LDLR* (100%), *APOB* (97%), *PCSK9* (95%), and other genes. Most centres (96%) incorporated pathogenicity interpretation into their reports, adhering largely to American College of Medical Genetics and Genomics guidelines.

Conclusion


Familial hypercholesterolaemia genetic testing practices vary widely across countries surveyed, emphasizing the need for global standardization to enhance accuracy and comparability of FH diagnoses worldwide. We suggest that genetic testing should include the three FH-causing genes and ideally the five associated/phenocopy genes.

Lay summary

This was a global survey from centres within 55 countries within the Familial Hypercholesterolaemia Studies Collaboration (FHSC). The study evaluated the current practice of genetic testing for familial hypercholesterol- aemia (FH), an inherited condition characterized by high cholesterol levels and increased cardiovascular risk, since a definitive diagnosis is a key determinant of patient-centred care.

- The study found that while most centres screen for the three main FH genes and incorporate interpretation on whether a genetic change is disease causing, notable differences existed in the reasons for referring for a test and laboratory testing techniques among and within centres from high- and non-high-income countries. Among testing techniques, next-generation sequencing was the predominant method for testing index cases, while Sanger sequencing was commonly used for relatives. The study also found that about one-third of centres did not test for other important genetic changes called copy-number variants (CNVs).
- To ensure patients receive accurate diagnoses regardless of where they live, the authors recommend creating a global standard where testing always includes the three primary genes responsible for the condition, ideally alongside five other associated genes.

Graphical Abstract



Keywords

Genetic testing • Familial hypercholesterolaemia • Genetics • Pathogenicity interpretation • Global standardization

Introduction

Familial hypercholesterolaemia (FH) is one of the most common genetic disorders. It is caused by pathogenic variants in the *LDLR*, *APOB*, or *PCSK9* genes and manifests with lifelong elevated LDL cholesterol (LDL-C) and consequently increased risk of premature atherosclerotic cardiovascular disease (ASCVD).^{1–3} LDL-C-lowering medications are the cornerstone of treatment of FH and have been shown to substantially reduce the risk of ASCVD and death in this population, if initiated early.⁴

There is a clear value of genetic testing in FH, as it increases the precision of diagnosis, improves risk stratification, enables cascade testing, increases adherence to therapy, and even enables access to new therapies.⁵ Early detection is the key to preventing ASCVD and cardiovascular death in individuals with FH, but has proven challenging in most world regions, as it is estimated that 90% of cases worldwide are undetected.⁶ Although various clinical criteria have been developed to enable a clinical diagnosis of FH, a definitive diagnosis of heterozygous or homozygous FH (HeFH or HoFH) is only possible via genetic testing.⁵ The 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines for the management of dyslipidaemias recommend that FH should be diagnosed using clinical criteria and confirmed, where possible, by genetic testing.⁷ Screening for FH is recommended to identify index cases, followed by cascade testing in families, to enable early detection.^{5,8} Various countries have implemented, or are in the process of implementing, different screening strategies for FH detection in children and adults. Most screening programmes for FH include genetic testing as part of the diagnostic process.⁵

As FH awareness increases among clinicians through policy advocacy, and as genetic testing becomes more accessible worldwide, there remain important uncertainties in how FH testing is conducted in practice. Key knowledge gaps include information on which clinical criteria prompt healthcare providers to request genetic testing for FH in adults and children, which laboratory methods are used, and how these approaches differ across countries and healthcare settings, particularly between high-income and non-high-income regions. Addressing these questions is crucial for developing standardized guidelines for FH genetic testing.⁹ To explore these uncertainties, we conducted a survey of current practices across centres from 55 countries participating in the global Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry, the largest registry of patients with FH to date. The aim is to provide an overview of current practices, highlight areas for improvement, and provide recommendations for best practices for FH genetic testing, to support the standardization of FH detection worldwide.

Methods

The FHSC registry¹⁰ currently consists of more than 80 000 FH participants from 68 countries, with 77 investigators worldwide, including patients with a clinical and/or a genetic diagnosis of HeFH or HoFH. A detailed description of the FH participants included in the registry has been published elsewhere.^{11,12} The FHSC project is registered at ClinicalTrials.gov, NCT04272697.

The survey questionnaire is provided in the [Supplementary material](#). The questions focused on the reasons prompting a referral for genetic testing, as well as genetic testing methodologies employed at the centres within each participating country. FHSC national lead investigators (NLI) from all 68 countries within the EAS FHSC registry that participated in the registry at the time of the present study were invited to complete the FH Genetics Methods Survey. The final deadline to complete the survey was June 2024, 1 year after the survey invitation was sent to NLIs.

Data from the survey were reviewed and cleaned by querying the respective NLIs where needed. Where data were provided from more than one centre within a given country, the inputs were merged into a single response. The analysis was descriptive, providing information on the number (and %) of centres adopting certain methods or approaches to genetic testing. The list of centres from countries included in each United Nations (UN) region (defined according to the United Nations Statistics Division¹³) or income category (defined according to the World Bank¹⁴) in this study is shown in [Table 1](#). An expanded version of the methods is available in the [Supplementary material](#).

Results

Survey completion rate and countries included

A total of 68 countries fulfilled the eligibility criteria for inclusion in the survey and were invited to participate. National lead investigator (NLI) responses received covered 55 of 68 (81%) countries. Among these, 52 countries contributed a single-centre response (52 responses), and three countries provided multiple-centre responses (nine responses), which were merged by country. This yielded 55 aggregated responses, one per country, hereafter referred to as ‘centres’. The countries with responding NLIs are shown in [Table 1](#), classified by UN region, UN subregion, and country income status.

Criteria for requesting a genetic test

Adults

Among the 55 centres surveyed, 54 (98%) specified the criteria used for genetic testing referral. Of the latter, 47 (87%) indicated that referral for genetic testing in adults was primarily based upon fulfilling established clinical diagnostic criteria for the probability of having FH, such as Dutch Lipid Clinic Network (DLCN),¹⁵ Make Early Diagnosis to Prevent Early Death (MEDPED),¹⁶ Simon-Broome,¹⁷ specific country criteria (e.g. Canada and Japan), or a combination of these approaches ([Figure 1](#); [Supplementary material online, Figure S1](#)). The DLCN was the most frequently used clinical criterion, utilized in 34 centres (72%). The DLCN threshold prompting referral for genetic testing varied among centres, with eight centres setting it at 6 points, four centres at 5 points, and three centres at 3 points. In some cases, no specific DLCN score was defined. Simon-Broome was used in three centres (6.4%), MEDPED in one centre (2.1%), and a combination of more than one criterion was considered in seven centres (15%).

Twenty (37%) of the respondent centres incorporated individual classical features of FH into their referral process for genetic testing, either as a supplement to the established clinical criteria or as sole considerations. These features included elevated LDL-C, premature CVD, cutaneous FH signs (xanthoma), and

Table 1 United Nations region, United Nations subregion, and income status of countries with responding FHSC national lead investigators

UN region	UN subregion	Income status	
		High-income	Non-high-income
Africa	Northern Africa		Egypt
	Sub-Saharan Africa		South Africa
Americas	Latin America and the Caribbean	Chile, Uruguay	Argentina, Brazil, Mexico
	Northern America	Canada	
Asia	Central Asia		Uzbekistan
	Eastern Asia	Hong Kong, Japan, Taiwan	China
	South-Eastern Asia	Singapore	Malaysia, Thailand, Vietnam
	Southern Asia		India, Iran, Pakistan, Sri Lanka
	Western Asia	Cyprus, Israel, Kuwait, Oman, Saudi Arabia, United Arab Emirates	Lebanon
Europe	Eastern Europe	Bulgaria, Czechia, Hungary, Poland, Russia, Slovakia	Ukraine
	Northern Europe	Denmark, Estonia, Latvia, Lithuania, Norway, UK	
	Southern Europe	Greece, Italy, Malta, Portugal, Slovenia, Spain	Serbia
	Western Europe	Austria, Belgium, Germany, Luxembourg, the Netherlands, Switzerland	
Oceania	Oceania	Australia	

family history of FH diagnosis or FH features, or a combination of these (see [Supplementary material online, Figure S2A](#)). Among the 47 centres that primarily used established clinical criteria, 13 (28%) also considered individual classical FH features as supplementary options. In the seven (13%) centres where established clinical criteria were not used, referral for genetic testing was based solely on individual classical FH features (see [Supplementary material online, Figure S2B](#)). The FH features considered in these seven centres included elevated LDL-C (6/7, 86%), premature CVD (2/7, 29%), cutaneous signs (2/7, 29%), and family history of FH diagnosis or FH features (4/7, 57%) (see [Supplementary material online, Figure S2B](#)). The specific LDL-C thresholds were not specified by most centres, and where specified (12 centres), they ranged from 155 mg/dL (4.0 mmol/L) to 250 mg/dL (6.5 mmol/L). The most common cut-off was 190 mg/dL (4.9 mmol/L) (eight centres).

Children and adolescents

For children and adolescents, 53 (96%) of the 55 respondent centres indicated a reason for genetic testing referral, while the remaining two centres did not conduct genetic testing in children. Among the respondents, 42 (79%) performed genetic testing in children based on established clinical criteria ([Figure 1](#)). The most commonly used criteria were DLCN in 24 centres (57%) and Simon-Broome in five centres (12%). The EAS consensus statement² was considered in two centres (4.8%), while eight centres (19%) used a combination of two or more criteria.

Referral for genetic testing in children was based, in 21 (40%) of 53 centres, on individual FH features, which either supplemented established clinical criteria or were the only considered options (see [Supplementary material online, Figure S2A](#)). In 10 (21%) out of the 53 centres where established clinical criteria

were not utilized, genetic testing was conducted based solely on either elevated LDL-C in seven centres (64%), premature CVD in two centres (18%), cutaneous signs in two centres (18%), and/or family history of FH diagnosis/features in nine centres (91%) (see [Supplementary material online, Figure S2B](#)). LDL-C thresholds were not specified for the majority of centres, and when defined (13 centres), they ranged from 130 mg/dL (3.4 mmol/L) to 250 mg/dL (6.5 mmol/L). The commonest cut-off was 190 mg/dL (4.9 mmol/L) (eight centres).


Centres from high-income vs. non-high-income countries

A comparison between high- (n=38) and non-high-income (n=17) countries showed that only centres from high-income countries utilized Simon-Broome and MEDPED criteria for adults or children (see [Supplementary material online, Figures S3 and S4](#)). Notably, some centres from high-income countries also employed routine genetic testing for FH due to government implementation programmes.

Methods used for familial hypercholesterolaemia genetic testing

All centres reported using blood for DNA extraction for genetic testing, while 12 centres (22%) reported additionally using saliva.

The methods used for genetic testing in index cases are shown in [Figure 2](#) and [Supplementary material online, Figure S5](#). Most centres (35/55, 64%) used next-generation sequencing (NGS) with a specific gene panel. Other methods included exome sequencing (10/55, 18%), genome sequencing (2/55, 3.6%), Sanger sequencing screening of genes (6/55, 11%), and testing only for common country-specific variants (2/55, 3.6%). Most centres (36/55, 66%) tested for copy-number variants (CNVs),



86% (31/36) of these integrated CNV detection into NGS pipelines, and 14% (5/36) employed methods, such as multiplex ligation-dependent probe amplification (MLPA) (4/36) or microarray (1/36).

Regarding genetic testing in non-index cases, the methods used were significantly different from those for index cases ($P < 0.001$). Only 14 of the 51 (27%) centres reported using the same methodology as for index cases: 10 centres use NGS gene panels, two centres use exome sequencing, and two other centres test only for their own country-specific variants by Sanger sequencing (Figure 2B). The six centres that screen whole genes by Sanger sequencing in index cases also use Sanger sequencing to test only the variant identified in the family. For 31 centres, the methodology was different for non-index cases, using Sanger sequencing and/or MLPA to test only for the variant identified in the family. In four centres, non-index cases were not tested.

Centres from high-income vs. non-high-income countries

Testing techniques used in centres from high- and non-high-income countries were not significantly different for index cases ($P = 0.74$) or non-index cases ($P = 0.49$). Gene panel sequencing was the method preferred by centres from both high-income (24/38, 63%) and non-high-income (11/17, 65%) countries. In proportion, more centres from non-high-income countries used exome sequencing (24% vs. 16%) or testing of only country-specific variants (6% vs. 3%) to diagnose index cases than from high-income countries. Conversely, only centres from high-income countries used genome sequencing for FH diagnosis. Copy-number variants in index cases were tested in 26/38 (68%) centres from high-income countries and 10/17 (59%) centres from non-high-income countries (Figure 2B). Additional details on genetic testing practices by country of testing centre are provided in [Supplementary material online, Table S1](#).


Genes screened

Genes screened for by respondent centres are shown in Figure 3. All centres (55/55) screened for the *LDLR* gene. A total of 47 centres (85%) screened at least all exons of *LDLR*, *APOB*, and *PCSK9*, regardless of methodology; 32/38 (84%) from high-income countries and 15/17 (88%) from non-high-income countries. Two centres reported screening *LDLR* and *APOB* but not *PCSK9*, while three others screened *LDLR* and *PCSK9* and only specific variants/regions of *APOB*. One centre tested *LDLR* and *PCSK9* but not *APOB*, another centre tested only specific variants in *LDLR* and *APOB*, and another one only tested specific variants in *LDLR* and *PCSK9*. Regarding other FH-associated and FH phenocopy genes, 43 centres screened *LDLRAP1*, 37 screened *APOE* (and one tested only a specific variant), 29 screened *ABCG8*, 28 screened *ABCG5*, and 28 screened *LIPA*. In total, 24/55 (44%) centres screened all exons from the three FH-causing genes, the two FH-associated genes, and the three phenocopy genes; 15/38 (39%) from high-income countries and 9/17 (53%) from non-high-income countries.

A total of 13 centres across 13 countries reported screening for additional genes, although only genes related to the diagnosis of FH were requested. Of these, *APOC2* and *STAP1* were screened for by six centres; *ABCA1*, *APOA5*, and *LPL* by five centres; *CYP27A1* and *GPIHBP1* by four centres; *APOC3*, *LIPC*, *LMF1*, *LPA*, and *SORT1* by three centres; and *APOA1*, *APOA2*, *CREB3L3*, *DHCR7*, *EPHX2*, and *LCAT* by two centres.

Polygenic hypercholesterolaemia

A total of 18 centres across 18 countries (33%) reported testing for polygenic hypercholesterolaemia; 12/38 (32%) from high-income and 6/17 (35%) from non-high-income countries. Of these, eight performed it routinely, while 10 tested only if an FH causal variant was not identified or within the context of



research. In six centres, the polygenic score tested was the 6-SNP score described by Futema *et al.*,¹⁸ in seven centres it was the 12-SNP score (Talmud *et al.*¹⁹) (four of these tested both the 6- and 12-SNP scores), two centres tested the 10-SNP score (Wang *et al.*²⁰), one the 28-SNP score (Trinder *et al.*²¹), one the 223-SNP score from the Global Lipids Genetics Consortium,²² and the remaining four centres did not specify the specific score tested.

Variant pathogenicity interpretation

Pathogenicity reporting for identified variants is standard practice in 53 of 55 respondent centres with only two centres across two countries reporting the variant without providing pathogenicity interpretation. American College of Medical Genetics and Genomics (ACMG) guidelines were the most used criteria (45/53, 85%), either just the general 2015 version²³ (22/53, 42%), modified ACMG guidelines (2/53, 3.8%)

(either published^{24,25} or not), the Clinical Genome Resource (ClinGen) FH Variant Curation Expert Panel (VCEP) specification for *LDLR* variants²⁶ (1/53, 1.9%), or a combination of these (21/53, 40%), depending on the gene in question (Figure 4). The remaining seven centres stated their method for variant interpretation as consulting databases, such as ClinVar,²⁷ HGMD,²⁸ or LOVD,^{29–31} or using only segregation or *in silico* analysis.

ClinVar database was reported to be consulted in 26 centres, LOVD in four centres, HGMD in three centres, LSBD-UMD-*LDLR*³² in one centre, population frequency databases such as gnomAD and ExAC in four centres, and their own internal databases in two centres. Software tools used in variant interpretation were reported in three centres, namely Varsome, Franklin, and Cardio Classifier. Additionally, 16 centres reported using data from *in silico* analysis, four centres from functional analysis, and three centres from segregation analysis, either alone or in combination.




Figure 2 Continued




Figure 3 Genes screened for on genetic testing. N = 55 centres from 55 countries.

Discussion

The present study provides the most comprehensive description of current practices in FH genetic testing in centres from different countries worldwide using a systematic questionnaire and is the first such attempt globally. Based on the large differences observed in the centres from different countries, best practice recommendations from the FHSC Genetics Working Group for genetic testing of FH are given in a separate section.

Reasons for referral for genetic testing

Our results indicate that centres in most countries surveyed prefer the DLCN criteria over any other criteria for FH diagnosis in both adults and children. This is a surprising finding for children and adolescents, given that the DLCN criteria are not validated in children and lack age-specific LDL-C thresholds, which may limit its sensitivity in children.^{33,34} In fact, according to previous reported data from the FHSC, up to 50–75% of




Figure 4 Guidelines for determining pathogenicity. N = 55 centres from 55 countries. ACMG, American College of Medical Genetics and Genomics; FH VCEP, Familial Hypercholesterolemia Variant Curation Expert Panel.

children/adolescents with genetic FH could be missed (i.e. clinically not suspected to have FH) if LDL-C thresholds similar to those from DLCN were applied.¹² This preference for DLCN might come from a smaller proportion of paediatric cases in those countries, a larger focus on diagnosing children only by cascade screening, or a lack of awareness of the limitations of DLCN with regard to diagnosing FH in children. Unfortunately, this survey did not differentiate genetic referring for index cases vs. relatives, so cascade screening approaches were not recorded. Simon–Broome criteria and the EAS consensus paper,² which specify paediatric LDL-C thresholds, as well as specific paediatric guidelines like the one from the Japanese Atherosclerosis Society,³⁵ for example, are better suited for diagnosing FH in younger populations.^{12,36} Future studies should assess the effectiveness of adapting DLCN thresholds for paediatric populations to improve diagnostic accuracy.³⁷

Dutch Lipid Clinic Network is the most used in centres from both high- and non-high-income countries most likely due to it being recommended by the ESC guidelines on cardiovascular disease.³⁸ Make Early Diagnosis to Prevent Early Death and Simon–Broome are only used in a few centres, mostly in high-income countries. This difference is most likely due to historical guideline adoption, since the data required to apply Simon–Broome and DLCN are largely the same—LDL values, family history, and physical findings—and thus should not reflect differences in resource availability or healthcare infrastructure.

Some of the respondents in the survey reported using more than one of the established clinical criteria, possibly to increase diagnostic inclusivity. Differences in sensitivity and specificity among frameworks, such as DLCN, Simon–Broome, and MEDPED, suggest that no single framework is universally optimal³⁹ and that combining these criteria may capture cases missed by individual systems. However, this raises questions about the need to tailor diagnostic tools to reflect the genetic, environmental, and demographic characteristics of specific populations. Using more permissive criteria, such as LDL-C thresholds alone, may increase identification of potential FH cases, particularly in cases where family history or more detailed data might be lacking.⁴⁰


However, this strategy increases the number of genetic tests necessary, potentially straining resource-limited systems. Alternatively, strict criteria may exclude positive cases with borderline LDL-C concentrations. Striking a balance between sensitivity and specificity is essential, particularly considering specific local prevalence and diagnostic tools.

Familial hypercholesterolaemia genetic testing methodologies

Centres across most countries reported using NGS with a specific gene panel. However, only 47 centres screened the three FH genes, and only 24 included the five genes of FH phenocopies, as recently recommended.⁵ We note that centres from several countries reported including the *STAP1* gene in their FH testing panel, even though recent data have demonstrated that variants in this gene do not cause FH.^{41,42}

Centres from 12 countries reported using NGS for both index and non-index cases, which is not economically sustainable, as the cost is at least 10 times higher than genotyping in relatives only the variant identified in the index case. In non-index cases, it is only necessary to test the specific variant by either Sanger sequencing of the appropriate exon or MLPA in cases with CNVs. We noted that the use of NGS in non-index cases was more frequently reported by centres from non-high-income than from high-income countries. We hypothesize that this practice might reflect limited access to alternative methodologies rather than a deliberate strategic choice.

Copy-number variants are known to account for ~10% of *LDLR* variants⁴³; however, 34% of centres do not incorporate CNV analysis into their NGS pipelines. This omission is remarkable, as the data for CNV detection are often embedded within NGS results and should be accessible using appropriate bioinformatic tools. This is especially important in an FH population genetic screening context. Including CNV detection in existing pipelines would significantly enhance diagnostic yield at minimal additional cost.



This heterogeneity in testing practices will inevitably lead to different diagnostic ability, as some techniques are more comprehensive than others. The higher rate of false negatives will directly impact patient care, namely not allowing cascade screening in families and preventing treatment optimization.

Polygenic hypercholesterolaemia

The role of polygenic hypercholesterolaemia in FH diagnosis is increasingly recognized,⁴⁴ but its clinical utility remains uncertain. Although still at risk of ASCVD, the polygenic hypercholesterolaemia group has a lower risk than those with monogenic FH⁴⁵ and may not require the intensive lipid-lowering therapy recommended for monogenic FH patients. Currently, centres from only 18 of the 55 countries surveyed reported testing for polygenic hypercholesterolaemia, and most test only when a genetic FH diagnosis is not reached or in a research context. It is relevant to highlight that, although this questionnaire did not question who were the patients being tested for polygenic scores, these are not validated for children. Reporting polygenic findings alongside monogenic results might provide context for otherwise unexplained elevated LDL-C concentrations in adults, but consistent reporting guidelines are needed to standardize their interpretation and clinical utility, as can be seen in the high variability of scores used (6-, 12-, 10-, 28-, or 223-SNP scores).

Variant classification

Our results reveal that reporting variant pathogenicity is standard practice in almost all centres included in this study and that ACMG guidelines²³ are widely used. Whenever gene-specific guidelines and expert panel reviewed classifications (3-star) in ClinVar are available, as is the case for *LDLR*,⁴⁶ they should be prioritized over general ACMG criteria and 1- or 2-star classifications. Accuracy of variant classification is highly important and depends on access to reliable case-level data, robust databases, *in silico* tools, segregation analysis, functional studies, and population frequency data. Questionnaire responses

suggest that these tools may be under-reported, because ACMG guidelines rely heavily on these tools.

Recommendations for familial hypercholesterolaemia genetic testing

Following the results of this study, here are presented recommendations from the FHSC Working Group on Genetics, which aim to improve FH genetic testing worldwide. A summary of these recommendations is shown in [Figure 5](#).

Genes to test and methodologies

As recommended by the expert panel on genetic testing for FH,⁵ the best genetic test for FH is the use of an NGS panel of eight genes, including the three FH-causing genes (*LDLR*, *APOB*, and *PCSK9*), two associated genes (*APOE* and *LDLRAP1*), and three phenocopy genes (*LIPA*, *ABCG5*, and *ABCG8*), as biallelic (likely) pathogenic variants in these five genes can present a clinical phenotype similar to FH (except p.Leu167del in *APOE*, which in heterozygosity has been associated with FH⁴⁷). In countries where NGS is not possible, FH genetic testing can be performed by Sanger sequencing of each exon of the three FH-causing genes, as in the past. For specific populations with founder effects, the amplification and sequencing of specific fragments where the most common variants are found, or the use of arrays with those variants, can also be used, with the caveat that it must be acknowledged that only those fragments were analysed. Arrays and other selective methods should only be used if they are comprehensive methods with all variants described, so the diagnostic probability is high. Whole exome sequencing (WES) and whole genome sequencing (WGS) with a subsequent analysis of at least the eight genes referred can also be used, but most probably it is not the most cost-effective method in most countries (especially WGS). For family studies (cascade screening), the most cost-effective method is polymerase chain reaction (PCR) amplification and Sanger sequencing of the

fragment containing the variant found in the family, or MLPA if the variant is a large rearrangement. Using NGS methods for cascade screening can increase the cost 10-fold.

It is crucial to have a method to detect large rearrangements (CNVs), since these constitute ~10% of all variants found in *LDLR*. For NGS, there are software to analyse large rearrangements, and for labs that do not use NGS, MLPA should be performed. The use of arrays for large rearrangements, as comparative genomic hybridization (CGH) arrays, should only be used if those arrays can detect single exon duplications or deletions, because usually those arrays only detect larger rearrangements. In *LDLR*, there are several single exon deletions or duplications that can be missed by this method.

Since the clinical utility of polygenic risk scores in hypercholesterolaemia still remains uncertain, at this time, there is no specific recommendation whether to test or not and how to report it.

Variant interpretation

The most challenging part of the genetic diagnosis is the interpretation of the clinical significance of the variants found. In 2015, the ACMG published a general guideline²³ to classify pathogenicity of variants for genetic testing. The ClinGen FH VCEP has developed specific guidelines for the classification of *LDLR* variants,²⁶ and a dedicated team of biocurators and experts are classifying all *LDLR* variants in ClinVar.²⁷ Variants in *APOB* and *PCSK9* have still to be classified with the ACMG general guidelines,²³ including all Sequence Variant Interpretation working group-specific recommendations.⁴⁸ However, specific guidelines are in development for these two genes.

The classification of a variant is a complex, but crucial, procedure that requires access to a large set of evidence, such as variant type, localization, variant effect, frequency data in public databases, number of unrelated clinical FH cases with the variant, segregation data in families, functional studies, and *in silico* predictors. It is of great importance that research groups and clinical labs share their findings, including case-level data, in public databases, such as ClinVar.

The best practice should be to perform the ACMG classification (according to specifications for *LDLR* or the general guideline with the general published adaptations for *APOB* and *PCSK9*) for each variant found in clinically diagnosed FH patients by each laboratory. ClinVar 3-star level classifications (which means that they were reviewed by the FH VCEP) can be used directly, but laboratories need to check and report the classification date, particularly for variants of uncertain significance (VUS), since more evidence could have been published in the interim, allowing for re-classification of the variant.

Reporting the results of genetic testing for familial hypercholesterolaemia

Only variants classified as likely pathogenic or pathogenic are considered actionable,²³ and so, many clinical FH patients with a VUS may need to wait until experts are able to gather enough evidence for their variant to change classification and have their diagnosis genetically confirmed (or not).

Following the Association for Clinical Genetic Science (ACGS),⁴⁹ when a likely pathogenic variant is found, the report should state that result is *consistent* with the clinical diagnosis, and if a pathogenic variant is found, the report should mention

that result *confirms* the clinical diagnosis. The European Society of Human Genetics (ESHG) states that VUS can be reported,⁵⁰ especially to medical geneticists. However, since there is the possibility that the referring physician may misinterpret a VUS as pathogenic or may not know how to handle this information, which could lead to a wrong diagnosis or hinder the search for the correct one, a report of a VUS should always be very well elucidated.⁵¹ If co-segregation data can change the variant classification, the request for a family study should be included in the report. For likely benign and benign variants, the report should be given as negative.⁵⁰ Although methods for genetic counselling were not covered in this questionnaire, genetic counselling is very important to help patients understand these nuances on the genetic reports.

Lipoprotein(a) measurement

Even though this survey did not collect information about lipoprotein(a) testing, it is important to mention that all patients with hypercholesterolaemia should perform a measurement of lipoprotein(a), as elevated lipoprotein(a) can contribute to a clinical diagnosis of FH in 25–30% of individuals with a clinical diagnosis of FH.^{52–54} This is particularly important, as those with both elevated lipoprotein(a) and FH have a higher risk of ASCVD than those only with high lipoprotein(a) or only with a genetic diagnosis of FH.⁵⁵

Strengths and limitations

This study is a comprehensive description of current practices in FH genetic testing in centres from 55 countries worldwide. However, the data from each centre are not necessarily representative of what is practiced across the whole country; rather, it represents the experience of the centres to which the FHSC NLIs are affiliated. These are often centres of excellence for FH management or research centres in their respective countries and thus may reflect best available practice within a given country. Hence, the practices captured within this survey may represent better-resourced settings than the actual practice in other centres within the same country. In addition, collaborations within the FHSC, particularly between centres from high-income and non-high-income countries, have, in some cases, facilitated access to more expensive genotyping methods. Consequently, the information reported for some non-high-income countries may not fully reflect the methods available nationwide. While our findings give a broad, and potentially somewhat optimistic, overview of patterns of genetic testing methods across world regions, they do not represent a comprehensive country-level mapping of these methods. Nevertheless, the information derived should be useful in identifying key gaps in practice and outlining recommendations for optimal genetic testing for FH.

Conclusions

In summary, we report on the practices of FH genetic testing in clinical centres from 55 countries within the FHSC, spanning six continents. A wide variability was observed in the reasons prompting referrals for genetic testing, as well as in the methodologies used for genetic assays and reporting. These findings highlight the influence of country-specific approaches, including variations in healthcare infrastructure, resources, and policies.

Based on these observations, we provide recommendations aimed at optimizing FH genetic testing worldwide, but we acknowledge the importance of considering the local contexts and specific needs of individual countries.

Supplementary material

Supplementary material is available at *European Journal of Preventive Cardiology*.

Acknowledgements

A list of contributors of country data for this study is available as [Supplementary material](#).

Author contributions

Joana Rita Chora (Formal analysis, Methodology, Writing—original draft, Writing—review & editing [equal]), Irene Karungi (Data curation, Formal analysis, Methodology, Writing—original draft, Writing—review & editing [equal]), Amany Elshorbagy (Conceptualization, Data curation, Project administration, Supervision, Writing—review & editing [equal]), Christophe A.T. Stevens (Data curation [lead], Writing—review & editing [supporting]), Antonio J. Vallejo-Vaz (Data curation, Writing—review & editing [supporting]), Kanika I. Dharmayat (Data curation, Writing—review & editing [supporting]), Marianne Abifadel (Methodology, Writing—review & editing [supporting]), Carlos A. Aguilar-Salinas (Methodology, Writing—review & editing [supporting]), Khalid F. Alhabib (Methodology, Writing—review & editing [supporting]), Wael Almahmeed (Methodology, Writing—review & editing [supporting]), Fahad Alnouri (Methodology, Writing—review & editing [supporting]), Rodrigo Alonso (Methodology, Writing—review & editing [supporting]), Khalid Al-Rasadi (Methodology, Writing—review & editing [supporting]), Ahmad Al-Sarraf (Methodology, Writing—review & editing [supporting]), Marcello Arca (Methodology, Writing—review & editing [supporting]), Engy A. Ashaat (Methodology, Writing—review & editing [supporting]), Tester F. Ashavaid (Methodology, Writing—review & editing [supporting]), Maurizio Averna (Methodology, Writing—review & editing [supporting]), Maciej Banach (Methodology, Writing—review & editing [supporting]), Marianne Becker (Methodology, Writing—review & editing [supporting]), Christoph J. Binder (Methodology, Writing—review & editing [supporting]), Liam R. Brunham (Methodology, Writing—review & editing [supporting]), Alberico L. Catapano (Methodology, Writing—review & editing [supporting]), Pablo Corral (Methodology, Writing—review & editing [supporting]), Olivier S. Descamps (Methodology, Writing—review & editing [supporting]), Euridiki Drogari (Methodology, Writing—review & editing [supporting]), Ronen Durst (Methodology, Writing—review & editing [supporting]), Marat Ezhov (Methodology, Writing—review & editing [supporting]), Urh Groselj (Methodology, Writing—review & editing [supporting]), Mariko Harada-Shiba (Methodology, Writing—review & editing [supporting]), Kirsten B. Holven (Methodology, Writing—review & editing [supporting]), G. Kees Hovingh (Methodology, Writing—review & editing [supporting]), Weerapan Khovidhunkit (Methodology, Writing—review & editing [supporting]), Katarina Lalic (Methodology, Writing—review & editing [supporting]), Gustavs Latkovskis (Methodology, Writing—review & editing [supporting]), Ulrich Laufs (Methodology, Writing—review & editing [supporting]), Evangelos Liberopoulos (Methodology, Writing—review & editing [supporting]), Jie Lin (Methodology, Writing—review & editing [supporting]), Winfried März (Methodology, Writing—review & editing [supporting]), Pedro Mata (Methodology, Writing—review & editing [supporting]), Anne Thushara Matthias (Methodology, Writing—

review & editing [supporting]), André R. Miserez (Methodology, Writing—review & editing [supporting]), Olena Mitchenko (Methodology, Writing—review & editing [supporting]), Hapizah Mohd Nawawi (Methodology, Writing—review & editing [supporting]), Børge G. Nordestgaard (Methodology, Writing—review & editing [supporting]), Andrie G. Panayiotou (Methodology, Writing—review & editing [supporting]), György Paragh (Methodology, Writing—review & editing [supporting]), Zaneta Petrulioniene (Methodology, Writing—review & editing [supporting]), Arman Postadzhiyan (Methodology, Writing—review & editing [supporting]), Ximena Reyes (Methodology, Writing—review & editing [supporting]), Fouzia Sadiq (Methodology, Writing—review & editing [supporting]), Amirhossein Sahebkar (Methodology, Writing—review & editing [supporting]), Raul D. Santos (Methodology, Writing—review & editing [supporting]), J.P.S. Sawhney (Methodology, Writing—review & editing [supporting]), Heribert Schunkert (Methodology, Writing—review & editing [supporting]), Swarup A.V. Shah (Methodology, Writing—review & editing [supporting]), Aleksandr B. Shek (Methodology, Writing—review & editing [supporting]), Handrean Soran (Methodology, Writing—review & editing [supporting]), Ta-Chen Su (Methodology, Writing—review & editing [supporting]), Tavintharan Subramaniam (Methodology, Writing—review & editing [supporting]), Myra Tilney (Methodology, Writing—review & editing [supporting]), Brian Tomlinson (Methodology, Writing—review & editing [supporting]), Thanh Huong Truong (Methodology, Writing—review & editing [supporting]), Anne Tybjærg-Hansen (Methodology, Writing—review & editing [supporting]), Margus Viigimaa (Methodology, Writing—review & editing [supporting]), Branislav Vohnout (Methodology, Writing—review & editing [supporting]), Gerald F. Watts (Methodology, Writing—review & editing [supporting]), Shizuya Yamashita (Methodology, Writing—review & editing [supporting]), Kausik K. Ray (Conceptualization, Project administration [lead], Supervision, Writing—review & editing [equal]), Frederick J. Raal (Conceptualization, Supervision [supporting], Writing—review & editing [equal]), Steve E. Humphries (Conceptualization, Supervision [supporting], Writing—review & editing [equal]), Tomas Freiburger (Conceptualization, Methodology, Supervision [supporting], Writing—review & editing [equal]), and Mafalda Bourbon (Conceptualization, Supervision, Writing—review & editing [lead], Project administration, Writing—original draft [equal]).

Conflict of interest: Author's disclosures of interest are available as [Supplementary material](#).

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

- Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J* 2013;**34**:3478–3490.
- Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur Heart J* 2015;**36**:2425–2437.
- Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. *Eur Heart J* 2023;**44**:2277–2291.
- Brandts J, Ray KK. Familial hypercholesterolemia: JACC Focus Seminar 4/4. *J Am Coll Cardiol* 2021;**78**:1831–1843.
- Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. *J Am Coll Cardiol* 2018;**72**:662–680.

6. Xiang Z, Li JR, Wan WM, Li SH, Wu J. Familial hypercholesterolemia: current limitations and future breakthroughs. *World J Exp Med* 2024;**14**:99968.
7. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020;**41**:111–188.
8. Gidding SS, Wiegman A, Groselj U, Freiburger T, Peretti N, Dharmayat KI, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. *Eur J Prev Cardiol* 2022;**29**:2301–2311.
9. Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. *Nat Rev Cardiol* 2023;**20**:845–869.
10. Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. *Atheroscler Suppl* 2016;**22**:1–32.
11. Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, Dharmayat KI, Freiburger T, Hovingh GK, et al. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet* 2021;**398**:1713–1725.
12. Dharmayat KI, Vallejo-Vaz AJ, Stevens CAT, Brandts JM, Lyons ARM, Groselj U, et al. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. *Lancet* 2024;**403**:55–66.
13. The United Nations Statistics Division. Standard Country or Area Codes for Statistical Use. 1999. <https://unstats.un.org/unsd/methodology/m49/> (21 January 2024).
14. The World Bank. World Bank Country and Lending Groups. 2024. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> (21 January 2024).
15. Defesche JC, Lansberg PJ, Umans-Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with inherited hypercholesterolemia. *Semin Vasc Med* 2004;**4**:59–65.
16. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. *Am J Cardiol* 1993;**72**:171–176.
17. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. *BMJ* 1991;**303**:893–896.
18. Futema M, Shah S, Cooper JA, Li K, Whittall RA, Sharifi M, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. *Clin Chem* 2015;**61**:231–238.
19. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. *Lancet* 2013;**381**:1293–1301.
20. Wang J, Dron JS, Ban MR, Robinson JF, McIntyre AD, Alazzam M, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. *Arterioscler Thromb Vasc Biol* 2016;**36**:2439–2445.
21. Trinder M, Li X, DeCastro ML, Cermakova L, Sadananda S, Jackson LM, et al. Risk of premature atherosclerotic disease in patients with monogenic versus polygenic familial hypercholesterolemia. *J Am Coll Cardiol* 2019;**74**:512–522.
22. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet* 2013;**45**:1274.
23. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;**17**:405–423.
24. Chora JR, Medeiros AM, Alves AC, Bourbon M. Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with familial hypercholesterolemia: application of ACMG guidelines and implications for familial hypercholesterolemia diagnosis. *Genet Med* 2018;**20**:591–598.
25. Ellard S, Baple EL, Callaway A, Berry I, Forrester N, Turnbull C, et al. ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020 Recommendations ratified by ACGS Quality Subcommittee on 4 th February 2020. <https://doi.org/10.1101/531210>.
26. Chora JR, Iacocca MA, Tichý L, Wand H, Kurtz CL, Zimmermann H, et al. The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification. *Genet Med* 2022;**24**:293–306.
27. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res* 2018;**46**:D1062–D1067.
28. Stenson PD, Mort M, Ball E V, Shaw K, Phillips AD, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. *Hum Genet* 2014;**133**:1–9.
29. Fokkema IFAC, den Dunnen JT, Taschner PEM. LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. *Hum Mutat* 2005;**26**:63–68.
30. Fokkema IFAC, Taschner PEM, Schaafsma GCP, Celli J, Laros JFJ, den Dunnen JT. LOVD v.2.0: the next generation in gene variant databases. *Hum Mutat* 2011;**32**:557–563.
31. Leigh S, Futema M, Whittall R, Taylor-Beadling A, Williams M, den Dunnen JT, et al. The UCL low-density lipoprotein receptor gene variant database: pathogenicity update. *J Med Genet* 2017;**54**:217–223.
32. Villéger L, Abifadel M, Allard D, Rabès JP, Thiart R, Kotze MJ, et al. The UMD-LDLR database: additions to the software and 490 new entries to the database. *Hum Mutat* 2002;**20**:81–87.
33. Boccatonda A, Rossi I, D’Ardes D, Cocomello N, Perla F, Bucciarelli B, et al. Comparison between different diagnostic scores for the diagnosis of familial hypercholesterolemia: assessment of their diagnostic accuracy in comparison with genetic testing. *Eur Heart J* 2020;**41**:ehaa946.3206.
34. Schmieder RS, Krefting J, Ates S, Schlieben LD, Arens S, Kordonouri O, et al. Clinical scores fail to sufficiently identify children with familial hypercholesterolemia. *Eur J Prev Cardiol* 2026;**33**:361–369.
35. Harada-Shiba M, Ohtake A, Sugiyama D, Tada H, Dobashi K, Matsuki K, et al. Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022. *J Atheroscler Thromb* 2023;**30**:531.
36. Fu HY, Matsunaga K, Inoue T, Tani R, Funatsuki K, Iwase T, et al. Improved efficiency of the clinical diagnostic criteria for familial hypercholesterolemia in children: a comparison of the Japan Atherosclerosis Society Guidelines of 2017 and 2022. *J Atheroscler Thromb* 2024;**31**:1048–1057.
37. Kafol J, Miranda B, Sikonja R, Sikonja J, Wiegman A, Medeiros AM, et al. Proposal of a Familial Hypercholesterolemia Pediatric Diagnostic Score (FH-PeDS). *Eur J Prev Cardiol* 2025:zwaf352.
38. Visseren F, Mach F, Smulders YM, Carballo D, Koskinas KC, Böck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;**42**:3227–3337.
39. National Institute for Health and Care Excellence. *Familial Hypercholesterolaemia: Identification and Management: Evidence Reviews for Case-Finding, Diagnosis and Statin Monotherapy*. London: National Institute for Health and Care Excellence; 2017.
40. Ferch M, Galli L, Fellingner P, Baumgartner-Parzer S, Sunder-Plassmann R, Krychtiuk K, et al. Performance of LDL-C only compared to the Dutch Lipid Clinic Network Score for screening of familial hypercholesterolaemia: the Austrian experience and literature review. *Eur J Prev Cardiol* 2025;**32**:249–258.
41. Loaiza N, Hartgers ML, Reeskamp LF, Balder JW, Rimbart A, Baziotti V, et al. Taking one step back in familial hypercholesterolemia: STAP1 does not alter plasma LDL (Low-Density Lipoprotein) cholesterol in mice and humans. *Arterioscler Thromb Vasc Biol* 2020;**40**:973–985.
42. Lamiqiz-Moneo I, Restrepo-Córdoba MA, Mateo-Gallego R, Bea AM, del Pino Alberiche-Ruano M, García-Pavía P, et al. Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia. *Atherosclerosis* 2020;**292**:143–151.
43. Iacocca MA, Chora JR, Carrié A, Freiburger T, Leigh SE, Defesche JC, et al. ClinVar database of global familial hypercholesterolemia-associated DNA variants. *Hum Mutat* 2018;**39**:1631–1640.
44. Futema M, Bourbon M, Williams M, Humphries SE. Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. *Atherosclerosis* 2018;**277**:457–463.
45. Trinder M, Francis GA, Brunham LR. Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease. *JAMA Cardiol* 2020;**5**:390–399.
46. Chora JR, Iacocca MA, Tichý L, Wand H, Kurtz CL, Zimmermann H, et al. The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification On behalf of the ClinGen Familial Hypercholesterolemia Expert Panel. *Genet Med* 2022;**24**:293–306.
47. Cenarro A, Etxebarria A, de Castro-Orós I, Stef M, Bea AM, Palacios L, et al. The p.Leu167del mutation in APOE gene causes autosomal dominant

- hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes. *J Clin Endocrinol Metab* 2016;**101**:2113–2121.
48. Sequence Variant Interpretation Working Group—ClinGen | Clinical Genome Resource | SVI General Recommendations for Using ACMG/AMP Criteria. <https://clinicalgenome.org/working-groups/sequence-variant-interpretation/> (20 November 2024).
 49. Wallis Y, Payne S, Mcanulty C, Bodmer D, Sistermans E, Robertson K, et al. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics. 2013:16 https://www.acgs.uk.com/media/10791/evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_-_finalpdf.pdf.
 50. Deans ZC, Ahn JW, Carreira IM, Dequeker E, Henderson M, Lovrecic L, et al. Recommendations for reporting results of diagnostic genomic testing. *Eur J Hum Genet* 2022;**30**:1011–1016.
 51. Claustres M, Kožich V, Dequeker E, Fowler B, Hehir-Kwa JY, Miller K, et al. Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic). *Eur J Hum Genet* 2014;**22**:160–170.
 52. Langsted A, Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolemia: a prospective cohort study. *Lancet Diabetes Endocrinol* 2016;**4**:577–587.
 53. Hedegaard BS, Nordestgaard BG, Kanstrup HL, Thomsen KK, Bech J, Bang LE, et al. High lipoprotein(a) may explain one-quarter of clinical familial hypercholesterolemia diagnoses in Danish lipid clinics. *J Clin Endocrinol Metab* 2024;**109**:659–667.
 54. Medeiros AM, Alves AC, Miranda B, Chora JR, Bourbon M, Garabal M, et al. Unraveling the genetic background of individuals with a clinical familial hypercholesterolemia phenotype. *J Lipid Res* 2024;**65**:100490–1.
 55. Hedegaard BS, Bork CS, Kaltoft M, Klausen IC, Schmidt EB, Kamstrup PR, et al. Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease. *J Am Coll Cardiol* 2022;**80**:1998–2010.